Literature DB >> 9305608

Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis.

J D Bailly1, A Skladanowski, A Bettaieb, V Mansat, A K Larsen, G Laurent.   

Abstract

The purpose of this study was to characterize mitoxantrone-induced cytotoxicity in KG1a and TF-1, two P-glycoprotein expressing AML cell lines which display early differentiation phenotypes, compared to more mature HL-60 and U937 cells. KG1a and TF-1 cells were found to be 30-40-fold more resistant to mitoxantrone than HL-60 and U937 cells. Uptake and efflux of mitoxantrone were similar for all cell lines. Moreover, a potent P-glycoprotein blocker (PSC833) had no impact on either accumulation or efflux. No differences were found in the appearance and removal of mitoxantrone-induced DNA-protein complexes. These results suggest that resistance of KG1a and TF-1 cells is not related to a decreased interaction between mitoxantrone and topoisomerase II. Further studies showed that the mechanisms of cell death were different for sensitive and resistant cell lines. Thus, mitoxantrone induced rapid apoptotic cell death in sensitive cells as indicated by characteristic morphological changes and both high molecular weight and internucleosomal DNA fragmentation. In contrast, mitoxantrone induced a G2-M block in resistant cells followed by a progressive loss of viability with necrotic features. Neither oligonucleosomal nor large DNA fragments were detected in these cells during a post-treatment period of up to 96 h. Finally, drug-induced activation of the AP-1 transcription factor was higher in resistant cell lines than in sensitive ones whereas activation of NF-kappaB was comparable. Therefore, our study provides evidence that certain AML cells display natural resistance to mitoxantrone which is independent of drug transport and drug-target interactions but appears to be associated with the inability of the drug to induce apoptosis in these cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305608     DOI: 10.1038/sj.leu.2400762

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Authors:  Kshitij Verma; Tianzhu Zang; Trevor M Penning; Paul C Trippier
Journal:  J Med Chem       Date:  2019-03-25       Impact factor: 7.446

2.  Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.

Authors:  Jia Rao; Duo-Rong Xu; Fei-Meng Zheng; Zi-Jie Long; Sheng-Shan Huang; Xing Wu; Wei-Hua Zhou; Ren-Wei Huang; Quentin Liu
Journal:  J Transl Med       Date:  2011-05-19       Impact factor: 5.531

3.  OPN b and c Isoforms Doubtless Veto Anti-angiogenesis Effects of Curcumin in Combination with Conventional AML Regiment

Authors:  Akram Mirzaei; Seyed H Ghaffari; Mohsen Nikbakht; Hosein Kamranzadeh Foumani; Mohammad Vaezi; Saeed Mohammadi; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2017-09-27

4.  Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.

Authors:  May Levin; Michal Stark; Yishai Ofran; Yehuda G Assaraf
Journal:  Cancer Cell Int       Date:  2021-01-14       Impact factor: 5.722

Review 5.  Mitochondrial metabolism as a target for acute myeloid leukemia treatment.

Authors:  Svetlana B Panina; Jingqi Pei; Natalia V Kirienko
Journal:  Cancer Metab       Date:  2021-04-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.